AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7247635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29023829 — intervention group
Group type: EXPERIMENTAL
Intervention: Domagrozumab
Number of subjects: 0
Study 29023829 — intervention group
Group type: EXPERIMENTAL
Intervention: Allometric approaches for dosing per body weight
Number of subjects: 0
Study 27491736 — intervention group
Group type: EXPERIMENTAL
Intervention: sub-CIS <2
Number of subjects: 50
Study 27491736 — intervention group
Group type: EXPERIMENTAL
Intervention: sub-CIS=2
Number of subjects: 50
Study 27491736 — intervention group
Group type: EXPERIMENTAL
Intervention: sub-CIS=2 plus good revascularization
Number of subjects: 50
Study 24634462 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) - 15 mg/16 hr nicotine patches
Number of subjects: 33
Study 24634462 — intervention group
Group type: COMPARATOR
Intervention: Smoking
Number of subjects: 33
Study 23664370 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (rapidly cooled to 32-33°C for 48-72 hours, then rewarmed by 0.5-1.0°C every 12-24 hours)
Number of subjects: 77
Study 23664370 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (maintained at 36.5-37.5°C)
Number of subjects: 77
Study 23664370 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 77
Study 23664370 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 77
Study 20378563 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg/m²
Number of subjects: 325
Study 20378563 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 60 mg/m²
Number of subjects: 325
Study 20378563 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 325
Study 20378563 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 325
Study 19026890 — intervention group
Group type: EXPERIMENTAL
Intervention: Smear layer present (smear [+]) - irrigated with NaOCl (5.25%)
Number of subjects: 50
Study 19026890 — intervention group
Group type: COMPARATOR
Intervention: Smear layer absent (smear [‐]) - irrigated with EDTA (17%) and NaOCl (5.25%)
Number of subjects: 50
Study 16925285 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac perioperatively continued for 24 hours postoperatively
Number of subjects: 50
Study 16925285 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil intraoperatively as part of balanced anesthesia
Number of subjects: 50
Study 12538377 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg i.v.
Number of subjects: 40
Study 10987706 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam (2 g/1 g) administered intravenously every 6 h
Number of subjects: 96
Study 10987706 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (2 g) administered intravenously every 6 h
Number of subjects: 96
Study 10987706 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam
Number of subjects: 96
Study 10987706 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 96
Study 10987706 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with histories of injection drug abuse
Number of subjects: 96
Study 10987706 — intervention group
Group type: COMPARATOR
Intervention: Patients without histories of injection drug abuse
Number of subjects: 96
Study 8605592 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (400 mg/day) plus Zidovudine (500 mg/day)
Number of subjects: 67
Study 8605592 — intervention group
Group type: COMPARATOR
Intervention: Dideoxicytidine (2.25 mg/day) plus Zidovudine (500 mg/day)
Number of subjects: 67
Study 8605592 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine plus Zidovudine
Number of subjects: 67
Study 1396726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (trimethoprim-sulfamethoxazole) 40 mg/kg/day
Number of subjects: 24
Study 1396726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (trimethoprim-sulfamethoxazole) 120 mg/kg/day
Number of subjects: 24
Study 3933261 — intervention group
Group type: EXPERIMENTAL
Intervention: Midthoracic epidural morphine (5 mg injected at the end of the operation and subsequently three times a day)
Number of subjects: 30
Study 3933261 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar epidural morphine (5 mg injected at the end of the operation and subsequently three times a day)
Number of subjects: 30
Study 3933261 — intervention group
Group type: EXPERIMENTAL
Intervention: Midthoracic epidural morphine
Number of subjects: 30
Study 3933261 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar epidural morphine
Number of subjects: 30
Study 31420883 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 hr sitting with 10 calf raises every 10 min (CALF)
Number of subjects: 20
Study 31420883 — intervention group
Group type: COMPARATOR
Intervention: 3 hr sitting without intermittent calf raises (CON)
Number of subjects: 20
Study 29576304 — intervention group
Group type: EXPERIMENTAL
Intervention: dTap-IPVB (Boostrix-IPV, GSK)
Number of subjects: 387
Study 29576304 — intervention group
Group type: COMPARATOR
Intervention: dTap-IPVR (Repevax, Sanofi Pasteur)
Number of subjects: 387
Study 29576304 — intervention group
Group type: EXPERIMENTAL
Intervention: dTap-IPVB
Number of subjects: 387
Study 29576304 — intervention group
Group type: COMPARATOR
Intervention: dTap-IPVR
Number of subjects: 387
Study 27857632 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal exercise-based physical therapy with whole-body vibration (WBV) therapy plus traction (IBI group)
Number of subjects: 125
Study 27857632 — intervention group
Group type: COMPARATOR
Intervention: Multimodal exercise-based physical therapy without WBV therapy plus traction (FOTO group)
Number of subjects: 125
Study 25849961 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival autograft (CAG) with fibrin glue
Number of subjects: 65
Study 25849961 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane graft (AMG) with fibrin glue
Number of subjects: 65
Study 25849961 — intervention group
Group type: COMPARATOR
Intervention: Control group (CAG)
Number of subjects: 65
Study 25849961 — intervention group
Group type: COMPARATOR
Intervention: Control group (AMG)
Number of subjects: 65
Study 22849580 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel at 60 mg/m2
Number of subjects: 0
Study 22849580 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel at 60 mg/m2 plus bevacizumab at 15 mg/kg
Number of subjects: 0
Study 20417879 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Education Program (NEP)
Number of subjects: 51
Study 20417879 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 18683667 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump surgery (n=20)
Number of subjects: 40
Study 18683667 — intervention group
Group type: COMPARATOR
Intervention: Off-pump surgery (n=20)
Number of subjects: 40
Study 15911947 — intervention group
Group type: EXPERIMENTAL
Intervention: IV diltiazem 0.25 mg/kg (maximum 25 mg)
Number of subjects: 40
Study 15911947 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 0.15 mg/kg (maximum 10 mg)
Number of subjects: 40
Study 12888588 — intervention group
Group type: EXPERIMENTAL
Intervention: ABLC 3 mg/kg/day for 5 days (ABLC-5)
Number of subjects: 57
Study 12888588 — intervention group
Group type: EXPERIMENTAL
Intervention: ABLC 3 mg/kg/day for 10 days (ABLC-10)
Number of subjects: 57
Study 12888588 — intervention group
Group type: COMPARATOR
Intervention: Meglumine antimoniate 20 mg Sbv/kg/day for 28 days
Number of subjects: 57
Study 12888588 — intervention group
Group type: COMPARATOR
Intervention: Meglumine antimoniate
Number of subjects: 57
Study 12888588 — intervention group
Group type: EXPERIMENTAL
Intervention: ABLC groups
Number of subjects: 57
Study 10574596 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine Leiomyosarcomas (ULMS)
Number of subjects: 40
Study 10574596 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrauterine Leiomyosarcomas (EULMS)
Number of subjects: 40
Study 10574596 — intervention group
Group type: COMPARATOR
Intervention: Uterine and Extrauterine Leiomyomas (LM)
Number of subjects: 40
Study 8669720 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombosis patients (3)
Number of subjects: 5
Study 8669720 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemorrhage patient (1)
Number of subjects: 5
Study 8669720 — intervention group
Group type: COMPARATOR
Intervention: Healthy subject (1)
Number of subjects: 5
Study 1706248 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereoscopic stimuli (dynamic random-dot stereograms presented as a stereoscopic checkerboard pattern)
Number of subjects: 13
Study 1706248 — intervention group
Group type: COMPARATOR
Intervention: Contrast stimuli (conventional 2-dimensional checkerboard reversal stimulus)
Number of subjects: 13
Study 6729152 — intervention group
Group type: EXPERIMENTAL
Intervention: etidocaine 1%
Number of subjects: 20
Study 6729152 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.75%
Number of subjects: 20
Study 6729152 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5%
Number of subjects: 20
Study 30636691 — intervention group
Group type: EXPERIMENTAL
Intervention: RFM visible during training
Number of subjects: 400
Study 30636691 — intervention group
Group type: COMPARATOR
Intervention: RFM masked during training (Control)
Number of subjects: 400
Study 29089207 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage with carrier oil
Number of subjects: 284
Study 29089207 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage with aromatherapy oil
Number of subjects: 284
Study 29089207 — intervention group
Group type: COMPARATOR
Intervention: Standard nursing care only
Number of subjects: 284
Study 26897384 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary exclusion technique
Number of subjects: 64
Study 26897384 — intervention group
Group type: COMPARATOR
Intervention: Conventional procedure
Number of subjects: 64
Study 25250691 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking across a HIGH plank (anxiety-inducing condition)
Number of subjects: 31
Study 25250691 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking across a LOW plank (less anxiety-inducing condition)
Number of subjects: 31
Study 25250691 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking across a HIGH plank (anxiety-inducing condition) in OFF state
Number of subjects: 31
Study 20423278 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG)
Number of subjects: 337
Study 20423278 — intervention group
Group type: COMPARATOR
Intervention: Yuzpe regimen (high dose combined oral contraceptive pills)
Number of subjects: 337
Study 15802944 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment measures including the Relationship Questionnaire, Relationship Style Questionnaire, and Experiences in Close Relationships inventory.
Number of subjects: 99
Study 12837046 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol (10 mg/day)
Number of subjects: 36
Study 12837046 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin (20 mg/day)
Number of subjects: 36
Study 9396545 — intervention group
Group type: EXPERIMENTAL
Intervention: Open fetal surgery for repair of CDH
Number of subjects: 11
Study 9396545 — intervention group
Group type: COMPARATOR
Intervention: Standard postnatal care
Number of subjects: 11
Study 8122720 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 3282868 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid (900 mg daily for 14 days)
Number of subjects: 80
Study 3282868 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (40 mg daily)
Number of subjects: 80
Study 3282868 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment by physician
Number of subjects: 80
Study 11228804 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 0
Study 11228804 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 0
Study 30836984 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation (PS) and Unconditional Cash Transfer (UCT) with Health Education (HE)
Number of subjects: 588
Study 30836984 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional Cash Transfer (UCT) with Health Education (HE)
Number of subjects: 588
Study 30836984 — intervention group
Group type: COMPARATOR
Intervention: Comparison arm
Number of subjects: 588
Study 29433668 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive radio campaign
Number of subjects: 14
Study 29433668 — intervention group
Group type: COMPARATOR
Intervention: No radio media campaign (Control)
Number of subjects: 14
Study 26865444 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-apposing, sirolimus-eluting STENTYS stent
Number of subjects: 152
Study 26865444 — intervention group
Group type: COMPARATOR
Intervention: Zotarolimus-eluting balloon-expandable stent
Number of subjects: 152
Study 24457472 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial infusion of p53 gene (Gendicine, 10vp) combined with hydroxycamptothecin (20 mg), once a week for 3 weeks
Number of subjects: 48
Study 24457472 — intervention group
Group type: COMPARATOR
Intervention: Arterial infusion with hydroxycamptothecin (20 mg)
Number of subjects: 48
Study 24457472 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial infusion of p53 gene (Gendicine)
Number of subjects: 48
Study 22237855 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 22237855 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical antipsychotics
Number of subjects: 0
Study 22237855 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study 22237855 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 22237855 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 19931427 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg/day (e-group, N=24)
Number of subjects: 48
Study 19931427 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (c-group, N=24)
Number of subjects: 48
Study 19931427 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg/day (e-group)
Number of subjects: 48
Study 17090635 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention consisting of health, nutrition, and exercise classes plus an aerobic exercise program
Number of subjects: 73
Study 17090635 — intervention group
Group type: COMPARATOR
Intervention: Control group (studied twice without receiving the intervention)
Number of subjects: 73
Study 15203786 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine skin patches (21 mg/24 hr)
Number of subjects: 0
Study 15203786 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine (10 mg/day)
Number of subjects: 0
Study 15203786 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nicotine skin patches and mecamylamine
Number of subjects: 0
Study 15203786 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to denicotinized cigarettes
Number of subjects: 0
Study 15203786 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to cigarettes with different menthol flavor
Number of subjects: 0
Study 15203786 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilated-filter (low tar and nicotine) cigarettes
Number of subjects: 0
Study 15203786 — intervention group
Group type: COMPARATOR
Intervention: Mentholated cigarettes for menthol smokers
Number of subjects: 0
Study 15203786 — intervention group
Group type: COMPARATOR
Intervention: Nonmentholated cigarettes for nonmenthol smokers
Number of subjects: 0
Study 11254917 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (FEN) 200 mg/day
Number of subjects: 20
Study 11254917 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study 9736816 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5-10 mg)
Number of subjects: 76
Study 9736816 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (2-8 mg)
Number of subjects: 76
Study 9736816 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cilazapril and doxazosin (half doses)
Number of subjects: 76
Study 9736816 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg) added after initial treatments
Number of subjects: 76
Study 8047423 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% nitroglycerin ointment
Number of subjects: 80
Study 8047423 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 80
Study 2929853 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (50, 100, 150, or 200 micrograms/kg body wt); 55 recipients of 100 or 200 micrograms/kg doses received a second identical dose the next day
Number of subjects: 200
Study 2929853 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 200
Study 29550406 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated whole-cell oral cholera vaccine (OCV)
Number of subjects: 204700
Study 29550406 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 204700
Study 28963124 — intervention group
Group type: EXPERIMENTAL
Intervention: PULSE (40g whey protein as hourly drinks, 4g per drink)
Number of subjects: 30
Study 28963124 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLUS (40g whey protein as two boluses, 28g at 0h and 12g at 7h)
Number of subjects: 30
Study 28963124 — intervention group
Group type: EXPERIMENTAL
Intervention: LL‐RE (light-load resistance exercise, leg extensions, 10 sets of 36 repetitions at 16% 1RM)
Number of subjects: 30
Study 28963124 — intervention group
Group type: COMPARATOR
Intervention: Placebo (hourly isocaloric maltodextrin drinks)
Number of subjects: 30
Study 26298694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure bladder indicator
Number of subjects: 130
Study 26298694 — intervention group
Group type: COMPARATOR
Intervention: Epidural pressure measurement
Number of subjects: 130
Study 26298694 — intervention group
Group type: COMPARATOR
Intervention: Bladder working pressure measurement
Number of subjects: 130
Study 22664478 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4/PTK/ZK
Number of subjects: 85
Study 22664478 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4/placebo
Number of subjects: 85
Study 21621727 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made shoe orthotics for 6 weeks
Number of subjects: 50
Study 21621727 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no treatment for 6 weeks)
Number of subjects: 50
Study 21621727 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made shoe orthotics for 12 weeks (after initial 6 weeks)
Number of subjects: 50
Study 19337169 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 53
Study 19337169 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 53
Study 16489468 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 T MR angiography
Number of subjects: 27
Study 16489468 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheter angiography (CCA)
Number of subjects: 27
Study 15192630 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant administration (Survanta, Ross Laboratories, Columbus, Ohio)
Number of subjects: 132
Study 15192630 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (control group)
Number of subjects: 132
Study 15192630 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant administration
Number of subjects: 132
Study 10701031 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen 100 mg (two doses: one at the end of surgery and one 12 hours postoperatively)
Number of subjects: 0
Study 10701031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9347201 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (3 mg infused intravenously)
Number of subjects: 13
Study 9347201 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo, infused intravenously)
Number of subjects: 13
Study 8155034 — intervention group
Group type: EXPERIMENTAL
Intervention: Methazolamide (50 mg twice daily) for 6 weeks
Number of subjects: 17
Study 8155034 — intervention group
Group type: EXPERIMENTAL
Intervention: Methazolamide (50 mg twice daily) for 12 weeks
Number of subjects: 17
Study 8155034 — intervention group
Group type: EXPERIMENTAL
Intervention: Best corrected visual acuity assessment
Number of subjects: 17
Study 3020692 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV alternating with VP-16 plus cisplatin for a total of six treatment cycles
Number of subjects: 0
Study 3020692 — intervention group
Group type: COMPARATOR
Intervention: CAV (standard regimen)
Number of subjects: 0
Study 31610074 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit
Number of subjects: 47
Study 31610074 — intervention group
Group type: COMPARATOR
Intervention: Smartphone app
Number of subjects: 47
Study 31610074 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviewing symptoms weekly
Number of subjects: 47
Study 31610074 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for reviewing symptoms
Number of subjects: 47
Study 31610074 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring sleep
Number of subjects: 47
Study 31610074 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to self-monitoring
Number of subjects: 47
Study 31610074 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for self-monitoring
Number of subjects: 47
Study 29398910 — intervention group
Group type: EXPERIMENTAL
Intervention: PEM-NWE
Number of subjects: 75
Study 29398910 — intervention group
Group type: EXPERIMENTAL
Intervention: PEM-PRE
Number of subjects: 75
Study 29398910 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 75
Study 27388859 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery training intervention for video laryngoscopy (VL)
Number of subjects: 35
Study 27388859 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving mastery training after 3 months
Number of subjects: 35
Study 27388859 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall attempts to demonstrate mastery
Number of subjects: 35
Study 24485549 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocrystalline silver dressing (Acticoat™)
Number of subjects: 76
Study 24485549 — intervention group
Group type: COMPARATOR
Intervention: Plain gauze dressing (control)
Number of subjects: 76
Study 23164205 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered 1% lidocaine
Number of subjects: 376